ACTRN12606000380594招募中不适用
An Open Label, Dose Titration Study of Sevelamer Carbonate dosed Three Times A Day in the control of phosphorus levels in Hyperphosphatemic Chronic Kidney Disease Patients Not On Dialysis
Genzyme Corporation, USA0 个研究点目标入组 40 人开始时间: 2006年8月29日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •CKD patients not on dialysis; documented hyperphosphatemia without the use of a phosphate binder or after washout from current phosphate binder; signed informed consent.
排除标准
- •Known hypersensitivity to the investigational product or any constituents of the study drug; active bowel obstruction, dysphagia, swallowing disorder or severe gastrointestinal (GI) motility disorders; in the opinion of the investigator, patient has poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, HIV infection, or any clinically significant unstable medical condition; pregnant or breast-feeding; evidence of active malignancy except for basal cell carcinoma of the skin; unable to comply with the requirements of the study.
研究者
相似试验
进行中（未招募）
1 期
An open label, dose titration study of sevelamer carbonate tablets dosed three times a day in hyperphosphatemic chronic kidney disease patients not on dialysisChronic kidney diseaseMedDRA version: 8.0Level: LLTClassification code 10009122EUCTR2005-003233-41-GBGenzyme Europe BV28
进行中（未招募）
1 期
An open label, dose titration study of sevelamer carbonate tablets dosed three times a day in hyperphosphatemic chronic kidney disease patients not on dialysisMedDRA version: 8.0Level: LLTClassification code 10009122Chronic kidney diseaseEUCTR2005-003233-41-DKGenzyme Europe BV55
进行中（未招募）
不适用
An open label, dose titration study of sevelamer carbonate tablets dosed three times a day in hyperphosphatemic chronic kidney disease patients not on dialysisChronic kidney diseaseEUCTR2005-003233-41-DEGenzyme Europe BV55
已完成
3 期
An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD PatientsRenal Failure ChronicNCT02332811Genzyme, a Sanofi Company96
已完成
不适用
Evaluate the therapeutic effects of Sevelamer to reduce blood sugar levels, HbA1c, blood lipids and hs-CRP in patients with diabetic nephropathyDiabetic nephropathy.Diabetic nephropathyIRCT2016100423559N5Vice chancellor for research, Ardabil University of Medical Sciences30